{"transactions":[{"id":698941,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-03T20:05:12.000Z","date":"2026-08-01","kind":"grant","planned":false,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on August 1, 2026. The shares underlying the option are scheduled to vest over three years in equal monthly installments from August 1, 2026 through August 1, 2029, subject to continuous service."}],"balance_after":18000,"derivative":{"exercise_price":3.51,"expiration_date":"2036-07-31","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001193125-26-330530","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526330530/ownership.xml","form_type":"4"}},{"id":730451,"issuer":{"id":6253,"kind":"organization","name":"PepGen Inc."},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-22T20:03:31.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting."}],"balance_after":34000,"derivative":{"exercise_price":1.79,"expiration_date":"2036-06-17","underlying":"Common Stock","underlying_shares":34000},"source":{"system":"sec-edgar","filing":"0001835597-26-000028","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1620743/000183559726000028/form4.xml","form_type":"4"}},{"id":741668,"issuer":{"id":5884,"kind":"organization","name":"Immuneering Corp"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2026-06-11T21:26:15.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":33350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 11, 2026, and will be fully vested and exercisable on June 11, 2027, or the date of the 2027 annual meeting of stockholders, whichever comes first."}],"balance_after":33350,"derivative":{"exercise_price":4.12,"expiration_date":"2036-06-11","underlying":"Class A Common Stock","underlying_shares":33350},"source":{"system":"sec-edgar","filing":"0001790340-26-000066","document":"wk-form4_1781213173.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1620743/000179034026000066/wk-form4_1781213173.xml","form_type":"4"}},{"id":955175,"issuer":{"id":5884,"kind":"organization","name":"Immuneering Corp"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2026-01-02T21:56:14.000Z","date":"2026-01-01","kind":"grant","planned":false,"acquired":true,"shares":7888,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Pursuant to the Immuneering Corporation Non-Employee Director Compensation Program (the \"Compensation Program\"), the reporting person elected to receive this stock option in lieu of receiving the cash Base Retainer (as defined in the Compensation Program)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable as to 25% of the shares subject to the option upon the reporting person completing three months of continuous service as a Non-Employee Director (as defined in the Compensation Program) following the grant date, such that the fourth and final installment will vest and become exercisable on the first anniversary of the grant date, subject in each case to such continuous service."}],"balance_after":7888,"derivative":{"exercise_price":6.58,"expiration_date":"2036-01-01","underlying":"Class A Common Stock","underlying_shares":7888},"source":{"system":"sec-edgar","filing":"0001790340-26-000004","document":"wk-form4_1767390971.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1620743/000179034026000004/wk-form4_1767390971.xml","form_type":"4"}},{"id":1109746,"issuer":{"id":5884,"kind":"organization","name":"Immuneering Corp"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-16T13:09:20.000Z","date":"2025-06-13","kind":"grant","planned":false,"acquired":true,"shares":33350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 13, 2025, and will be fully vested and exercisable on June 13, 2026, or the date of the 2026 annual meeting of stockholders, whichever comes first."}],"balance_after":33350,"derivative":{"exercise_price":1.9,"expiration_date":"2035-06-13","underlying":"Class A Common Stock","underlying_shares":33350},"source":{"system":"sec-edgar","filing":"0001790340-25-000071","document":"wk-form4_1750079353.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1620743/000179034025000071/wk-form4_1750079353.xml","form_type":"4"}},{"id":1119581,"issuer":{"id":6253,"kind":"organization","name":"PepGen Inc."},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-06T10:51:36.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting."}],"balance_after":16000,"derivative":{"exercise_price":1.51,"exercise_date":"2026-06-04","expiration_date":"2035-06-03","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001127602-25-016930","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1620743/000112760225016930/form4.xml","form_type":"4"}},{"id":1318611,"issuer":{"id":5884,"kind":"organization","name":"Immuneering Corp"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-01-02T21:06:31.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":23485,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Pursuant to the Immuneering Corporation Non-Employee Director Compensation Program (the \"Compensation Program\"), the reporting person elected to receive this stock option in lieu of receiving the cash Base Retainer (as defined in the Compensation Program)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable as to 25% of the shares subject to the option upon the reporting person completing three months of continuous service as a Non-Employee Director (as defined in the Compensation Program) following the grant date, such that the fourth and final installment will vest and become exercisable on the first anniversary of the grant date, subject in each case to such continuous service."}],"balance_after":23485,"derivative":{"exercise_price":2.2,"expiration_date":"2035-01-01","underlying":"Class A Common Stock","underlying_shares":23485},"source":{"system":"sec-edgar","filing":"0001790340-25-000005","document":"wk-form4_1735851984.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1620743/000179034025000005/wk-form4_1735851984.xml","form_type":"4"}},{"id":1472005,"issuer":{"id":6253,"kind":"organization","name":"PepGen Inc."},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-21T20:10:49.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting."}],"balance_after":13000,"derivative":{"exercise_price":16.8,"exercise_date":"2025-06-20","expiration_date":"2034-06-19","underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001127602-24-019123","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1620743/000112760224019123/form4.xml","form_type":"4"}},{"id":1480664,"issuer":{"id":5884,"kind":"organization","name":"Immuneering Corp"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2024-06-13T20:22:53.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":33350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 12, 2024, and will be fully vested and exercisable on June 12, 2025, or the date of the 2025 annual meeting of stockholders, whichever comes first."}],"balance_after":33350,"derivative":{"exercise_price":1.54,"expiration_date":"2034-06-12","underlying":"Class A Common Stock","underlying_shares":33350},"source":{"system":"sec-edgar","filing":"0001628280-24-028065","document":"wk-form4_1718310166.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1620743/000162828024028065/wk-form4_1718310166.xml","form_type":"4"}},{"id":1696499,"issuer":{"id":5884,"kind":"organization","name":"Immuneering Corp"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2024-01-02T21:31:36.000Z","date":"2024-01-01","kind":"grant","planned":false,"acquired":true,"shares":6879,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Pursuant to the Immuneering Corporation Non-Employee Director Compensation Program (the \"Compensation Program\"), the reporting person elected to receive this stock option in lieu of receiving the cash Base Retainer (as defined in the Compensation Program)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable as to 25% of the shares subject to the option upon the reporting person completing three months of continuous service as a Non-Employee Director (as defined in the Compensation Program) following the grant date, such that the fourth and final installment will vest and become exercisable on the first anniversary of the grant date, subject in each case to such continuous service."}],"balance_after":6879,"derivative":{"exercise_price":7.35,"expiration_date":"2034-01-01","underlying":"Class A Common Stock","underlying_shares":6879},"source":{"system":"sec-edgar","filing":"0001790340-24-000004","document":"wk-form4_1704231077.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1620743/000179034024000004/wk-form4_1704231077.xml","form_type":"4"}},{"id":1844194,"issuer":{"id":6253,"kind":"organization","name":"PepGen Inc."},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-26T20:13:14.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting."}],"balance_after":12000,"derivative":{"exercise_price":9.61,"exercise_date":"2024-06-22","expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001127602-23-019407","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1620743/000112760223019407/form4.xml","form_type":"4"}},{"id":1854281,"issuer":{"id":5884,"kind":"organization","name":"Immuneering Corp"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2023-06-15T20:44:09.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in substantially equal monthly installments over a one-year period with a vesting commencement date of June 14, 2023, and will be fully vested and exercisable on June 14, 2024, or the date of the 2024 annual meeting of stockholders, whichever comes first."}],"balance_after":17500,"derivative":{"exercise_price":9.32,"expiration_date":"2033-06-14","underlying":"Class A Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001790340-23-000039","document":"wk-form4_1686861839.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1620743/000179034023000039/wk-form4_1686861839.xml","form_type":"4"}},{"id":2050825,"issuer":{"id":6253,"kind":"organization","name":"PepGen Inc."},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-01-19T22:17:01.000Z","date":"2022-05-06","kind":"purchase","acquired":true,"shares":4166,"price":12,"value":49992.0,"ownership":{"direct":true},"balance_after":4166,"source":{"system":"sec-edgar","filing":"0001127602-23-001831","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1620743/000112760223001831/form4.xml","form_type":"4"}},{"id":2056456,"issuer":{"id":15490,"kind":"organization","name":"Imago BioSciences, Inc.","symbol":"IMGO"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-11T21:23:43.000Z","date":"2023-01-11","kind":"disposition_to_issuer","acquired":false,"shares":11904,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the \"Merger\"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. Pursuant to the Merger Agreement, each option to purchase common stock of the Issuer, whether vested or unvested, outstanding immeditately prior to the effective time of the Merger, were exchanged for a cash payment equal to (x) the aggregate number of shares of the Issuer's common stock subject to such option, multiplied by (y) the excess, if any, of $36.00 over the per share exercise price under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the \"Merger\"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. Pursuant to the Merger Agreement, each option to purchase common stock of the Issuer, whether vested or unvested, outstanding immeditately prior to the effective time of the Merger, were exchanged for a cash payment equal to (x) the aggregate number of shares of the Issuer's common stock subject to such option, multiplied by (y) the excess, if any, of $36.00 over the per share exercise price under such option."}],"balance_after":0,"derivative":{"exercise_price":15.65,"expiration_date":"2032-05-31","underlying":"Common Stock","underlying_shares":11904},"source":{"system":"sec-edgar","filing":"0000899243-23-001609","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1620743/000089924323001609/doc4.xml","form_type":"4"}},{"id":2056455,"issuer":{"id":15490,"kind":"organization","name":"Imago BioSciences, Inc.","symbol":"IMGO"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-11T21:23:43.000Z","date":"2023-01-11","kind":"disposition_to_issuer","acquired":false,"shares":23809,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the \"Merger\"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. Pursuant to the Merger Agreement, each option to purchase common stock of the Issuer, whether vested or unvested, outstanding immeditately prior to the effective time of the Merger, were exchanged for a cash payment equal to (x) the aggregate number of shares of the Issuer's common stock subject to such option, multiplied by (y) the excess, if any, of $36.00 over the per share exercise price under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the \"Merger\"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. Pursuant to the Merger Agreement, each option to purchase common stock of the Issuer, whether vested or unvested, outstanding immeditately prior to the effective time of the Merger, were exchanged for a cash payment equal to (x) the aggregate number of shares of the Issuer's common stock subject to such option, multiplied by (y) the excess, if any, of $36.00 over the per share exercise price under such option."}],"balance_after":0,"derivative":{"exercise_price":22.76,"expiration_date":"2031-11-16","underlying":"Common Stock","underlying_shares":23809},"source":{"system":"sec-edgar","filing":"0000899243-23-001609","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1620743/000089924323001609/doc4.xml","form_type":"4"}},{"id":2223052,"issuer":{"id":5884,"kind":"organization","name":"Immuneering Corp"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2022-06-23T20:59:03.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":14200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 21, 2022, and will be fully vested and exercisable on June 21, 2023, or the date of the 2023 annual meeting of stockholders, whichever comes first."}],"balance_after":14200,"derivative":{"exercise_price":4.63,"expiration_date":"2032-06-20","underlying":"Class A Common Stock","underlying_shares":14200},"source":{"system":"sec-edgar","filing":"0001415889-22-006897","document":"form4-06232022_010649.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1620743/000141588922006897/form4-06232022_010649.xml","form_type":"4"}},{"id":2244725,"issuer":{"id":15490,"kind":"organization","name":"Imago BioSciences, Inc.","symbol":"IMGO"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-03T20:42:42.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":11904,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day prior to the annual meeting in 2023 of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":11904,"derivative":{"exercise_price":15.65,"expiration_date":"2032-05-31","underlying":"Common Stock","underlying_shares":11904},"source":{"system":"sec-edgar","filing":"0001567619-22-012295","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1620743/000156761922012295/doc1.xml","form_type":"4"}},{"id":2268107,"issuer":{"id":5884,"kind":"organization","name":"Immuneering Corp"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2022-05-17T21:15:48.000Z","date":"2022-05-16","kind":"purchase","acquired":true,"shares":7000,"price":5,"value":35000.0,"ownership":{"direct":true},"balance_after":14000,"source":{"system":"sec-edgar","filing":"0001415889-22-005150","document":"form4-05172022_020524.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1620743/000141588922005150/form4-05172022_020524.xml","form_type":"4"}},{"id":2276176,"issuer":{"id":6253,"kind":"organization","name":"PepGen Inc."},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-10T22:50:23.000Z","date":"2022-05-06","kind":"grant","acquired":true,"shares":5833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest as follows: twenty-five percent (25%) on the one-year anniversary of the Grant Date and the remainder vesting in thirty-six (36) equal monthly installments, subject to the option recipient's continued service or employment with the Company on each applicable vesting date."}],"balance_after":5833,"derivative":{"exercise_price":12,"expiration_date":"2032-05-05","underlying":"Common Stock","underlying_shares":5833},"source":{"system":"sec-edgar","filing":"0000899243-22-017498","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1620743/000089924322017498/doc4.xml","form_type":"4"}},{"id":2502982,"issuer":{"id":15490,"kind":"organization","name":"Imago BioSciences, Inc.","symbol":"IMGO"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-19T22:59:20.000Z","date":"2021-11-17","kind":"grant","acquired":true,"shares":23809,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One thirty-sixth (1/36th) of the shares initially subject to the option will vest on each monthly anniversary measured from November 17, 2021 (the \"Vesting Commencement Date\"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":23809,"derivative":{"exercise_price":22.76,"expiration_date":"2031-11-16","underlying":"Common Stock","underlying_shares":23809},"source":{"system":"sec-edgar","filing":"0001567619-21-020884","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1620743/000156761921020884/doc1.xml","form_type":"4"}},{"id":2610299,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Stock Option  (right to buy)","published_at":"2021-08-09T20:09:55.000Z","date":"2021-08-05","kind":"exercise","acquired":false,"shares":7876,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional  6.25% of the shares each successive three month period thereafter."}],"balance_after":1124,"derivative":{"exercise_price":88.95,"expiration_date":"2025-12-18","underlying":"Common Stock","underlying_shares":7876},"source":{"system":"sec-edgar","filing":"0001735276-21-000079","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000079/edgardoc.xml","form_type":"4"}},{"id":2610298,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Performance Stock Option 2015 (right to buy)","published_at":"2021-08-09T20:09:55.000Z","date":"2021-08-05","kind":"exercise","acquired":false,"shares":2124,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020."}],"balance_after":11876,"derivative":{"exercise_price":88.95,"exercise_date":"2019-08-06","expiration_date":"2025-12-18","underlying":"Common Stock","underlying_shares":2124},"source":{"system":"sec-edgar","filing":"0001735276-21-000079","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000079/edgardoc.xml","form_type":"4"}},{"id":2610297,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-08-09T20:09:55.000Z","date":"2021-08-05","kind":"sale","acquired":false,"shares":10000,"price":188.95,"value":1889500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020."}],"balance_after":5132,"source":{"system":"sec-edgar","filing":"0001735276-21-000079","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000079/edgardoc.xml","form_type":"4"}},{"id":2610296,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-08-09T20:09:55.000Z","date":"2021-08-05","kind":"exercise","acquired":true,"shares":2124,"price":88.95,"value":188929.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020."}],"balance_after":15132,"source":{"system":"sec-edgar","filing":"0001735276-21-000079","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000079/edgardoc.xml","form_type":"4"}},{"id":2610295,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-08-09T20:09:55.000Z","date":"2021-08-05","kind":"exercise","acquired":true,"shares":7876,"price":88.95,"value":700570.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020."}],"balance_after":13008,"source":{"system":"sec-edgar","filing":"0001735276-21-000079","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000079/edgardoc.xml","form_type":"4"}},{"id":2614837,"issuer":{"id":5884,"kind":"organization","name":"Immuneering Corp"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2021-08-04T10:06:07.000Z","date":"2021-08-03","kind":"purchase","acquired":true,"shares":7000,"price":15,"value":105000.0,"ownership":{"direct":true},"balance_after":7000,"source":{"system":"sec-edgar","filing":"0001104659-21-099736","document":"tm2123807-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1620743/000110465921099736/tm2123807-7_4seq1.xml","form_type":"4"}},{"id":2634179,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Stock Option  (right to buy)","published_at":"2021-07-14T20:58:47.000Z","date":"2021-07-12","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional  6.25% of the shares each successive three month period thereafter."}],"balance_after":9000,"derivative":{"exercise_price":88.95,"expiration_date":"2025-12-18","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001735276-21-000053","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000053/edgardoc.xml","form_type":"4"}},{"id":2634178,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Stock Option  (right to buy)","published_at":"2021-07-14T20:58:47.000Z","date":"2021-07-12","kind":"exercise","acquired":false,"shares":1812,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional  6.25% of the shares each successive three month period thereafter."}],"balance_after":17188,"derivative":{"exercise_price":85,"expiration_date":"2029-02-27","underlying":"Common Stock","underlying_shares":1812},"source":{"system":"sec-edgar","filing":"0001735276-21-000053","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000053/edgardoc.xml","form_type":"4"}},{"id":2634177,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-07-14T20:58:47.000Z","date":"2021-07-12","kind":"sale","acquired":false,"shares":5000,"price":178.95,"value":894750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020."}],"balance_after":5132,"source":{"system":"sec-edgar","filing":"0001735276-21-000053","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000053/edgardoc.xml","form_type":"4"}},{"id":2634176,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-07-14T20:58:47.000Z","date":"2021-07-12","kind":"sale","acquired":false,"shares":1812,"price":179,"value":324348.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020."}],"balance_after":10132,"source":{"system":"sec-edgar","filing":"0001735276-21-000053","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000053/edgardoc.xml","form_type":"4"}},{"id":2634175,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-07-14T20:58:47.000Z","date":"2021-07-12","kind":"exercise","acquired":true,"shares":5000,"price":88.95,"value":444750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020."}],"balance_after":11944,"source":{"system":"sec-edgar","filing":"0001735276-21-000053","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000053/edgardoc.xml","form_type":"4"}},{"id":2634174,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-07-14T20:58:47.000Z","date":"2021-07-12","kind":"exercise","acquired":true,"shares":1812,"price":85,"value":154020.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020."}],"balance_after":6944,"source":{"system":"sec-edgar","filing":"0001735276-21-000053","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000053/edgardoc.xml","form_type":"4"}},{"id":2672348,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-06-11T20:13:48.000Z","date":"2021-06-09","kind":"sale","acquired":false,"shares":1734,"price":154,"value":267036.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020."}],"balance_after":5132,"source":{"system":"sec-edgar","filing":"0001735276-21-000047","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000047/edgardoc.xml","form_type":"4"}},{"id":2743243,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-04-21T22:21:20.000Z","date":"2021-04-20","kind":"tax_withholding","acquired":false,"shares":75,"price":134.4183,"value":10081.3725,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event."}],"balance_after":6866,"source":{"system":"sec-edgar","filing":"0001735276-21-000038","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000038/edgardoc.xml","form_type":"4"}},{"id":2743242,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-04-21T22:21:20.000Z","date":"2021-04-20","kind":"tax_withholding","acquired":false,"shares":2014,"price":131.75,"value":265344.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event."}],"balance_after":6941,"source":{"system":"sec-edgar","filing":"0001735276-21-000038","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000038/edgardoc.xml","form_type":"4"}},{"id":2743241,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-04-21T22:21:20.000Z","date":"2021-04-19","kind":"grant","acquired":true,"shares":4518,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 26, 2020, the reporting person was granted performance-based restricted stock units (PSU) in connection with the 2019 year-end compensation review.  One third of the PSU award vests upon the achievement of each of three specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the first performance criterion was met and one-third of the PSU award vested as of April 19, 2021."}],"balance_after":8955,"source":{"system":"sec-edgar","filing":"0001735276-21-000038","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000038/edgardoc.xml","form_type":"4"}},{"id":2830068,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Stock Option  (right to buy)","published_at":"2021-02-26T21:04:18.000Z","date":"2021-02-24","kind":"grant","acquired":true,"shares":17846,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the time-vested stock option portion of the reporting person's Annual Equity Award for 2020. The reporting person also received 9,566 performance stock units that will vest upon the achievement of four specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the performance stock units vest."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter."}],"balance_after":17846,"derivative":{"exercise_price":151.59,"expiration_date":"2031-02-23","underlying":"Common Stock","underlying_shares":17846},"source":{"system":"sec-edgar","filing":"0001735276-21-000022","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000022/edgardoc.xml","form_type":"4"}},{"id":2859694,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Performance Stock Option 2017 (right to buy)","published_at":"2021-02-16T21:06:55.000Z","date":"2021-02-11","kind":"grant","acquired":true,"shares":4584,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On March 1, 2018, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock in connection with the 2017 year-end compensation review. One third of the shares subject to the option vests upon the achievement of each of three specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the third performance criterion was met and the option vested as to the final one third of the shares as of February 11, 2021."}],"balance_after":10000,"derivative":{"exercise_price":119.13,"exercise_date":"2021-02-11","expiration_date":"2028-03-01","underlying":"Common Stock","underlying_shares":4584},"source":{"system":"sec-edgar","filing":"0001735276-21-000011","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000011/edgardoc.xml","form_type":"4"}},{"id":2859693,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-02-16T21:06:55.000Z","date":"2021-02-12","kind":"tax_withholding","acquired":false,"shares":106,"price":153.54,"value":16275.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event."}],"balance_after":4437,"source":{"system":"sec-edgar","filing":"0001735276-21-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000011/edgardoc.xml","form_type":"4"}},{"id":2859692,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-02-16T21:06:55.000Z","date":"2021-02-12","kind":"tax_withholding","acquired":false,"shares":1857,"price":156,"value":289692.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event."}],"balance_after":4543,"source":{"system":"sec-edgar","filing":"0001735276-21-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000011/edgardoc.xml","form_type":"4"}},{"id":2859691,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-02-16T21:06:55.000Z","date":"2021-02-11","kind":"grant","acquired":true,"shares":4166,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 28, 2019, the reporting person was granted performance-based restricted stock units (PSU) in connection with the 2018 year-end compensation review.  One third of the PSU award vests upon the achievement of each of three specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the second performance criterion was met and an additional one-third of the PSU award vested as of February 11, 2021."}],"balance_after":6400,"source":{"system":"sec-edgar","filing":"0001735276-21-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000011/edgardoc.xml","form_type":"4"}},{"id":2906248,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Stock Option  (right to buy)","published_at":"2021-01-15T21:03:27.000Z","date":"2021-01-13","kind":"exercise","acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional  6.25% of the shares each successive three month period thereafter."}],"balance_after":19000,"derivative":{"exercise_price":85,"expiration_date":"2029-02-27","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001735276-21-000006","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000006/edgardoc.xml","form_type":"4"}},{"id":2906247,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Stock Option  (right to buy)","published_at":"2021-01-15T21:03:27.000Z","date":"2021-01-13","kind":"exercise","acquired":false,"shares":3027,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional  6.25% of the shares each successive three month period thereafter."}],"balance_after":2164,"derivative":{"exercise_price":77.4,"expiration_date":"2024-09-22","underlying":"Common Stock","underlying_shares":3027},"source":{"system":"sec-edgar","filing":"0001735276-21-000006","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000006/edgardoc.xml","form_type":"4"}},{"id":2906246,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-01-15T21:03:27.000Z","date":"2021-01-13","kind":"sale","acquired":false,"shares":1027,"price":174,"value":178698.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020."}],"balance_after":2234,"source":{"system":"sec-edgar","filing":"0001735276-21-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000006/edgardoc.xml","form_type":"4"}},{"id":2906245,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-01-15T21:03:27.000Z","date":"2021-01-13","kind":"sale","acquired":false,"shares":3000,"price":170,"value":510000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020."}],"balance_after":3261,"source":{"system":"sec-edgar","filing":"0001735276-21-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000006/edgardoc.xml","form_type":"4"}},{"id":2906244,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-01-15T21:03:27.000Z","date":"2021-01-13","kind":"sale","acquired":false,"shares":5000,"price":169,"value":845000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020."}],"balance_after":6261,"source":{"system":"sec-edgar","filing":"0001735276-21-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000006/edgardoc.xml","form_type":"4"}},{"id":2906243,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-01-15T21:03:27.000Z","date":"2021-01-13","kind":"exercise","acquired":true,"shares":6000,"price":85,"value":510000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020."}],"balance_after":11261,"source":{"system":"sec-edgar","filing":"0001735276-21-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000006/edgardoc.xml","form_type":"4"}},{"id":2906242,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-01-15T21:03:27.000Z","date":"2021-01-13","kind":"exercise","acquired":true,"shares":3027,"price":77.4,"value":234289.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020."}],"balance_after":5261,"source":{"system":"sec-edgar","filing":"0001735276-21-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000006/edgardoc.xml","form_type":"4"}},{"id":2908554,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Stock Option  (right to buy)","published_at":"2021-01-13T21:05:05.000Z","date":"2021-01-12","kind":"exercise","acquired":false,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional  6.25% of the shares each successive three month period thereafter."}],"balance_after":5191,"derivative":{"exercise_price":77.4,"expiration_date":"2024-09-22","underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001735276-21-000004","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000004/edgardoc.xml","form_type":"4"}},{"id":2908553,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Stock Option  (right to buy)","published_at":"2021-01-13T21:05:05.000Z","date":"2021-01-12","kind":"exercise","acquired":false,"shares":1941,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional  6.25% of the shares each successive three month period thereafter."}],"balance_after":2370,"derivative":{"exercise_price":42.22,"expiration_date":"2026-12-20","underlying":"Common Stock","underlying_shares":1941},"source":{"system":"sec-edgar","filing":"0001735276-21-000004","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000004/edgardoc.xml","form_type":"4"}},{"id":2908552,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-01-13T21:05:05.000Z","date":"2021-01-12","kind":"sale","acquired":false,"shares":3000,"price":165,"value":495000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020."}],"balance_after":2234,"source":{"system":"sec-edgar","filing":"0001735276-21-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000004/edgardoc.xml","form_type":"4"}},{"id":2908551,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-01-13T21:05:05.000Z","date":"2021-01-12","kind":"sale","acquired":false,"shares":11941,"price":159,"value":1898619.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020."}],"balance_after":5234,"source":{"system":"sec-edgar","filing":"0001735276-21-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000004/edgardoc.xml","form_type":"4"}},{"id":2908550,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-01-13T21:05:05.000Z","date":"2021-01-12","kind":"exercise","acquired":true,"shares":13000,"price":77.4,"value":1006200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020."}],"balance_after":17175,"source":{"system":"sec-edgar","filing":"0001735276-21-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000004/edgardoc.xml","form_type":"4"}},{"id":2908549,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-01-13T21:05:05.000Z","date":"2021-01-12","kind":"exercise","acquired":true,"shares":1941,"price":42.22,"value":81949.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020."}],"balance_after":4175,"source":{"system":"sec-edgar","filing":"0001735276-21-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000004/edgardoc.xml","form_type":"4"}},{"id":2908548,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-01-13T21:05:05.000Z","date":"2021-01-11","kind":"sale","acquired":false,"shares":758,"price":154,"value":116732.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020."}],"balance_after":2234,"source":{"system":"sec-edgar","filing":"0001735276-21-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000004/edgardoc.xml","form_type":"4"}},{"id":3083757,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Stock Option  (right to buy)","published_at":"2020-07-14T20:03:49.000Z","date":"2020-07-13","kind":"exercise","acquired":false,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 11, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to the remaining shares ratably at the end of each three-month period thereafter over the following thirty-three (33) months"}],"balance_after":7500,"derivative":{"exercise_price":119.13,"expiration_date":"2028-02-28","underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0001735276-20-000090","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000090/edgardoc.xml","form_type":"4"}},{"id":3083756,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Stock Option  (right to buy)","published_at":"2020-07-14T20:03:49.000Z","date":"2020-07-13","kind":"exercise","acquired":false,"shares":23809,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 11, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional  6.25% of the shares each successive three month period thereafter."}],"balance_after":18191,"derivative":{"exercise_price":77.4,"expiration_date":"2024-09-22","underlying":"Common Stock","underlying_shares":23809},"source":{"system":"sec-edgar","filing":"0001735276-20-000090","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000090/edgardoc.xml","form_type":"4"}},{"id":3083755,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Stock Option  (right to buy)","published_at":"2020-07-14T20:03:49.000Z","date":"2020-07-13","kind":"exercise","acquired":false,"shares":1941,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 11, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional  6.25% of the shares each successive three month period thereafter."}],"balance_after":4311,"derivative":{"exercise_price":42.22,"expiration_date":"2026-12-20","underlying":"Common Stock","underlying_shares":1941},"source":{"system":"sec-edgar","filing":"0001735276-20-000090","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000090/edgardoc.xml","form_type":"4"}},{"id":3083754,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Performance Stock Option 2017 (right to buy)","published_at":"2020-07-14T20:03:49.000Z","date":"2020-07-13","kind":"exercise","acquired":false,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 11, 2020."}],"balance_after":5416,"derivative":{"exercise_price":119.13,"exercise_date":"2019-11-22","expiration_date":"2028-03-01","underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001735276-20-000090","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000090/edgardoc.xml","form_type":"4"}},{"id":3083753,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-07-14T20:03:49.000Z","date":"2020-07-13","kind":"sale","acquired":false,"shares":9530,"price":162.24,"value":1546147.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 11, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Sale prices ranged from $161.91 to $162.80."}],"balance_after":2992,"source":{"system":"sec-edgar","filing":"0001735276-20-000090","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000090/edgardoc.xml","form_type":"4"}},{"id":3083752,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-07-14T20:03:49.000Z","date":"2020-07-13","kind":"sale","acquired":false,"shares":15618,"price":161.32,"value":2519495.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 11, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Sale prices ranged from $160.90 to $161.89."}],"balance_after":12522,"source":{"system":"sec-edgar","filing":"0001735276-20-000090","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000090/edgardoc.xml","form_type":"4"}},{"id":3083751,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-07-14T20:03:49.000Z","date":"2020-07-13","kind":"sale","acquired":false,"shares":14236,"price":160.52,"value":2285162.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 11, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Sale prices ranged from $159.89 to $160.86."}],"balance_after":28140,"source":{"system":"sec-edgar","filing":"0001735276-20-000090","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000090/edgardoc.xml","form_type":"4"}},{"id":3083750,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-07-14T20:03:49.000Z","date":"2020-07-13","kind":"sale","acquired":false,"shares":1061,"price":159.22,"value":168932.42,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 11, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Sale prices ranged from $158.82 to $159.64."}],"balance_after":42376,"source":{"system":"sec-edgar","filing":"0001735276-20-000090","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000090/edgardoc.xml","form_type":"4"}},{"id":3083749,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-07-14T20:03:49.000Z","date":"2020-07-13","kind":"sale","acquired":false,"shares":2323,"price":158.27,"value":367661.21,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 11, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Sale prices ranged from $157.74 to $158.62."}],"balance_after":43437,"source":{"system":"sec-edgar","filing":"0001735276-20-000090","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000090/edgardoc.xml","form_type":"4"}},{"id":3083748,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-07-14T20:03:49.000Z","date":"2020-07-13","kind":"sale","acquired":false,"shares":4482,"price":157.16,"value":704391.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 11, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Sale prices ranged from $156.86 to $157.66."}],"balance_after":45760,"source":{"system":"sec-edgar","filing":"0001735276-20-000090","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000090/edgardoc.xml","form_type":"4"}},{"id":3083747,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-07-14T20:03:49.000Z","date":"2020-07-13","kind":"exercise","acquired":true,"shares":6250,"price":119.13,"value":744562.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 11, 2020."}],"balance_after":50242,"source":{"system":"sec-edgar","filing":"0001735276-20-000090","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000090/edgardoc.xml","form_type":"4"}},{"id":3083746,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-07-14T20:03:49.000Z","date":"2020-07-13","kind":"exercise","acquired":true,"shares":3750,"price":119.13,"value":446737.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 11, 2020."}],"balance_after":43992,"source":{"system":"sec-edgar","filing":"0001735276-20-000090","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000090/edgardoc.xml","form_type":"4"}},{"id":3083745,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-07-14T20:03:49.000Z","date":"2020-07-13","kind":"exercise","acquired":true,"shares":23809,"price":77.4,"value":1842816.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 11, 2020."}],"balance_after":40242,"source":{"system":"sec-edgar","filing":"0001735276-20-000090","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000090/edgardoc.xml","form_type":"4"}},{"id":3083744,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-07-14T20:03:49.000Z","date":"2020-07-13","kind":"exercise","acquired":true,"shares":1941,"price":42.22,"value":81949.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 11, 2020."}],"balance_after":16433,"source":{"system":"sec-edgar","filing":"0001735276-20-000090","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000090/edgardoc.xml","form_type":"4"}},{"id":3171963,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Stock Option  (right to buy)","published_at":"2020-04-22T20:07:08.000Z","date":"2020-04-20","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional  6.25% of the shares each successive three month period thereafter."}],"balance_after":42000,"derivative":{"exercise_price":77.4,"expiration_date":"2024-09-22","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001735276-20-000056","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000056/edgardoc.xml","form_type":"4"}},{"id":3171962,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-04-22T20:07:08.000Z","date":"2020-04-20","kind":"sale","acquired":false,"shares":10000,"price":139,"value":1390000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019."}],"balance_after":14492,"source":{"system":"sec-edgar","filing":"0001735276-20-000056","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000056/edgardoc.xml","form_type":"4"}},{"id":3171961,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-04-22T20:07:08.000Z","date":"2020-04-20","kind":"exercise","acquired":true,"shares":10000,"price":77.4,"value":774000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019."}],"balance_after":24492,"source":{"system":"sec-edgar","filing":"0001735276-20-000056","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000056/edgardoc.xml","form_type":"4"}},{"id":3179106,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-04-09T20:04:32.000Z","date":"2020-04-07","kind":"tax_withholding","acquired":false,"shares":75,"price":105.63,"value":7922.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event."}],"balance_after":14492,"source":{"system":"sec-edgar","filing":"0001735276-20-000047","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000047/edgardoc.xml","form_type":"4"}},{"id":3179105,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-04-09T20:04:32.000Z","date":"2020-04-07","kind":"tax_withholding","acquired":false,"shares":1858,"price":104.75,"value":194625.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event."}],"balance_after":14567,"source":{"system":"sec-edgar","filing":"0001735276-20-000047","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000047/edgardoc.xml","form_type":"4"}},{"id":3179104,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-04-09T20:04:32.000Z","date":"2020-04-07","kind":"grant","acquired":true,"shares":4167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 28, 2019, the reporting person was granted performance-based restricted stock units (PSU) in connection with the 2018 year-end compensation review.  This PSU award vests in three equal installments upon the later of one year from the date of grant and the achievement of each of three specific clinical development, regulatory or commercial events. One third of the shares subject to release under the PSU award vested upon the filing by the Company of its fourth NDA with the FDA, as determined by the compensation committee of the Company effective April 7, 2020."}],"balance_after":16425,"source":{"system":"sec-edgar","filing":"0001735276-20-000047","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000047/edgardoc.xml","form_type":"4"}},{"id":3241494,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Stock Option  (right to buy)","published_at":"2020-02-28T21:07:51.000Z","date":"2020-02-26","kind":"grant","acquired":true,"shares":24554,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the time-vested stock option portion of the reporting person's Annual Equity Award for 2019. The reporting person also received 13,554 performance stock units that will vest upon the achievement of three specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the performance stock units vest."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional  6.25% of the shares each successive three month period thereafter."}],"balance_after":24554,"derivative":{"exercise_price":118.05,"expiration_date":"2030-02-25","underlying":"Common Stock","underlying_shares":24554},"source":{"system":"sec-edgar","filing":"0001735276-20-000033","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000033/edgardoc.xml","form_type":"4"}},{"id":3277381,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Stock Option  (right to buy)","published_at":"2020-02-12T21:03:21.000Z","date":"2020-02-10","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional  6.25% of the shares each successive three month period thereafter."}],"balance_after":52000,"derivative":{"exercise_price":77.4,"expiration_date":"2024-09-22","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001735276-20-000014","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000014/edgardoc.xml","form_type":"4"}},{"id":3277380,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-02-12T21:03:21.000Z","date":"2020-02-10","kind":"sale","acquired":false,"shares":10000,"price":129,"value":1290000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019."}],"balance_after":12258,"source":{"system":"sec-edgar","filing":"0001735276-20-000014","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000014/edgardoc.xml","form_type":"4"}},{"id":3277379,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-02-12T21:03:21.000Z","date":"2020-02-10","kind":"exercise","acquired":true,"shares":10000,"price":77.4,"value":774000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019."}],"balance_after":22258,"source":{"system":"sec-edgar","filing":"0001735276-20-000014","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000014/edgardoc.xml","form_type":"4"}},{"id":3277382,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-02-12T21:02:34.000Z","date":"2020-01-27","kind":"exercise","acquired":true,"shares":3663,"price":77.4,"value":283516.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported on this Form 4 was made pursuant to Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019.  Reflects shares acquired upon the exercise by the reporting person of a stock option on January 27, 2020.  This acquisition was inadvertently omitted from the Form 4 filed on January 29, 2020 which reported both the exercise of the stock option and the subsequent sale of such acquired shares."}],"balance_after":12258,"source":{"system":"sec-edgar","filing":"0001735276-20-000013","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000013/edgardoc.xml","form_type":"4/A","original_submission_date":"2020-01-31"}},{"id":3296815,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Stock Option  (right to buy)","published_at":"2020-01-31T21:05:42.000Z","date":"2020-01-29","kind":"exercise","acquired":false,"shares":6337,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional  6.25% of the shares each successive three month period thereafter."}],"balance_after":62000,"derivative":{"exercise_price":77.4,"expiration_date":"2024-09-22","underlying":"Common Stock","underlying_shares":6337},"source":{"system":"sec-edgar","filing":"0001735276-20-000004","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000004/edgardoc.xml","form_type":"4"}},{"id":3296814,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-01-31T21:05:42.000Z","date":"2020-01-29","kind":"sale","acquired":false,"shares":6337,"price":119,"value":754103.0,"ownership":{"direct":true},"balance_after":8595,"source":{"system":"sec-edgar","filing":"0001735276-20-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000004/edgardoc.xml","form_type":"4"}},{"id":3296813,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-01-31T21:05:42.000Z","date":"2020-01-29","kind":"exercise","acquired":true,"shares":6337,"price":77.4,"value":490483.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019."}],"balance_after":14932,"source":{"system":"sec-edgar","filing":"0001735276-20-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000004/edgardoc.xml","form_type":"4"}},{"id":3298864,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Stock Option  (right to buy)","published_at":"2020-01-29T21:03:17.000Z","date":"2020-01-27","kind":"exercise","acquired":false,"shares":3663,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional  6.25% of the shares each successive three month period thereafter."}],"balance_after":68337,"derivative":{"exercise_price":77.4,"expiration_date":"2024-09-22","underlying":"Common Stock","underlying_shares":3663},"source":{"system":"sec-edgar","filing":"0001735276-20-000002","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000002/edgardoc.xml","form_type":"4"}},{"id":3298863,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Stock Option  (right to buy)","published_at":"2020-01-29T21:03:17.000Z","date":"2020-01-27","kind":"exercise","acquired":false,"shares":9374,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional  6.25% of the shares each successive three month period thereafter."}],"balance_after":6252,"derivative":{"exercise_price":42.22,"expiration_date":"2026-12-20","underlying":"Common Stock","underlying_shares":9374},"source":{"system":"sec-edgar","filing":"0001735276-20-000002","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000002/edgardoc.xml","form_type":"4"}},{"id":3298862,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Performance Stock Option 2016 (right to buy)","published_at":"2020-01-29T21:03:17.000Z","date":"2020-01-27","kind":"exercise","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019."}],"balance_after":0,"derivative":{"exercise_price":42.22,"exercise_date":"2019-08-06","expiration_date":"2026-12-20","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001735276-20-000002","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000002/edgardoc.xml","form_type":"4"}},{"id":3298861,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-01-29T21:03:17.000Z","date":"2020-01-27","kind":"sale","acquired":false,"shares":190,"price":120.21,"value":22839.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Sale prices ranged from $120.20 to $120.22"}],"balance_after":8595,"source":{"system":"sec-edgar","filing":"0001735276-20-000002","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000002/edgardoc.xml","form_type":"4"}},{"id":3298860,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-01-29T21:03:17.000Z","date":"2020-01-27","kind":"sale","acquired":false,"shares":6667,"price":119.53,"value":796906.51,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Sale prices ranged from $119.16 to $120.04"}],"balance_after":8785,"source":{"system":"sec-edgar","filing":"0001735276-20-000002","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000002/edgardoc.xml","form_type":"4"}},{"id":3298859,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-01-29T21:03:17.000Z","date":"2020-01-27","kind":"sale","acquired":false,"shares":13084,"price":118.61,"value":1551893.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Sale prices ranged from $118.15 to $119.12"}],"balance_after":15452,"source":{"system":"sec-edgar","filing":"0001735276-20-000002","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000002/edgardoc.xml","form_type":"4"}},{"id":3298858,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-01-29T21:03:17.000Z","date":"2020-01-27","kind":"sale","acquired":false,"shares":4100,"price":117.67,"value":482447.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Sale prices ranged from $117.10 to $118.10"}],"balance_after":28536,"source":{"system":"sec-edgar","filing":"0001735276-20-000002","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000002/edgardoc.xml","form_type":"4"}},{"id":3298857,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-01-29T21:03:17.000Z","date":"2020-01-27","kind":"sale","acquired":false,"shares":13631,"price":116.43,"value":1587057.33,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Sale prices ranged from $116.04 to $117.04"}],"balance_after":32636,"source":{"system":"sec-edgar","filing":"0001735276-20-000002","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000002/edgardoc.xml","form_type":"4"}},{"id":3298856,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-01-29T21:03:17.000Z","date":"2020-01-27","kind":"sale","acquired":false,"shares":3365,"price":115.55,"value":388825.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Sale prices ranged from $115.03 to $116.03"}],"balance_after":46267,"source":{"system":"sec-edgar","filing":"0001735276-20-000002","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000002/edgardoc.xml","form_type":"4"}},{"id":3298855,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-01-29T21:03:17.000Z","date":"2020-01-27","kind":"exercise","acquired":true,"shares":25000,"price":42.22,"value":1055500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019."}],"balance_after":49632,"source":{"system":"sec-edgar","filing":"0001735276-20-000002","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000002/edgardoc.xml","form_type":"4"}},{"id":3298854,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-01-29T21:03:17.000Z","date":"2020-01-27","kind":"exercise","acquired":true,"shares":9374,"price":42.22,"value":395770.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019."}],"balance_after":24632,"source":{"system":"sec-edgar","filing":"0001735276-20-000002","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000002/edgardoc.xml","form_type":"4"}},{"id":3331434,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Performance Stock Option 2017 (right to buy)","published_at":"2019-12-26T21:03:42.000Z","date":"2019-12-23","kind":"grant","acquired":true,"shares":4583,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 1, 2018, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One third of the shares subject to the option vest upon the achievement of each of three specific clinical development, regulatory or commercial events, as approved by our compensation committee. The compensation committee of the Company determined that the second performance criterion was met and the option vested as to the second one third of the shares as of December 23, 2019."}],"balance_after":9166,"derivative":{"exercise_price":119.13,"exercise_date":"2019-12-23","expiration_date":"2028-03-01","underlying":"Common Stock","underlying_shares":4583},"source":{"system":"sec-edgar","filing":"0001735276-19-000121","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527619000121/edgardoc.xml","form_type":"4"}},{"id":3358927,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Performance Stock Option 2017 (right to buy)","published_at":"2019-11-26T21:07:52.000Z","date":"2019-11-22","kind":"grant","acquired":true,"shares":4583,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On March 1, 2018, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One third of the shares subject to the option vest upon the achievement of each of three specific clinical development, regulatory or commercial events, as approved by our compensation committee. The compensation committee of the Company determined that the first performance criterion was met on November 22, 2019 and the option vested as to the first one third of the shares as of such date."}],"balance_after":4583,"derivative":{"exercise_price":119.13,"exercise_date":"2019-11-22","expiration_date":"2028-03-01","underlying":"Common Stock","underlying_shares":4583},"source":{"system":"sec-edgar","filing":"0001735276-19-000109","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527619000109/edgardoc.xml","form_type":"4"}},{"id":3358926,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2019-11-26T21:07:52.000Z","date":"2019-10-10","kind":"other","acquired":true,"shares":10,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by Managed Account"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."}],"balance_after":434,"source":{"system":"sec-edgar","filing":"0001735276-19-000109","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527619000109/edgardoc.xml","form_type":"4"}},{"id":3444739,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Performance Stock Option 2016 (right to buy)","published_at":"2019-08-07T20:17:36.000Z","date":"2019-08-06","kind":"grant","acquired":true,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On December 20, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option vested upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee. The compensation committee of the Company determined that the fourth performance criterion was met effective as of August 6, 2019 and the option vested as to the final one-quarter of the shares as of such date."}],"balance_after":25000,"derivative":{"exercise_price":42.22,"exercise_date":"2019-08-06","expiration_date":"2026-12-20","underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0001735276-19-000086","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527619000086/edgardoc.xml","form_type":"4"}},{"id":3444738,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Performance Stock Option 2015 (right to buy)","published_at":"2019-08-07T20:17:36.000Z","date":"2019-08-06","kind":"grant","acquired":true,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option vested upon the achievement of each of four specific clinical development or commercial events, as approved by our compensation committee. The compensation committee of the Company determined that the fourth performance criterion was met effective as of August 6, 2019 and the option vested as to the final one-quarter of the shares as of such date."}],"balance_after":14000,"derivative":{"exercise_price":88.95,"exercise_date":"2019-08-06","expiration_date":"2025-12-18","underlying":"Common Stock","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0001735276-19-000086","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527619000086/edgardoc.xml","form_type":"4"}},{"id":3444737,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2019-08-07T20:17:36.000Z","date":"2019-07-11","kind":"other","acquired":true,"shares":49,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by Managed Account"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."}],"balance_after":424,"source":{"system":"sec-edgar","filing":"0001735276-19-000086","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527619000086/edgardoc.xml","form_type":"4"}}],"next_cursor":"2019-08-07T20:17:36.000000Z,3444737"}